NCT03604783: Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors

NCT03604783
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic central nervous system metastatic disease that requires therapy
https://ClinicalTrials.gov/show/NCT03604783

Comments are closed.

Up ↑